Minneapolis, Minnesota 55455


Purpose:

This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy (independent of this study). Ideally, patients should begin consolidation chemotherapy no later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.


Criteria:

- Less than 30 years of age at diagnosis of neuroblastoma - End of Induction disease evaluation demonstrating CR, PR, MR or SD - Hematopoietic Recovery from last induction course of chemotherapy - No uncontrolled infection - Minimum frozen PBSCs of 2 x 10^6 CD34 cells/kg for each transplant are mandatory and a PBSC of 2 x 10^6 CD34 cells/kg for back-up are strongly recommended (thus, PBSC of no less than 6 x 10^6 CD34 cells/kg is encouraged). These must all be collected prior to the initiation of consolidation. - Adequate organ function defined as: - Hepatic: AST and ALT < 3 x upper limit of institutional normal; ALT ≤ 3 x ULN for age; total bilirubin ≤ 1.5 x ULN for age, if baseline was normal, > 1.0 1.5 x baseline if baseline was abnormal - Cardiac: shortening fraction ≥ 27% or ejection fraction ≥ 45%, no clinical congestive heart failure - Pulmonary: no evidence of dyspnea at rest and norequirement for supplemental oxygen - Renal: Creatinine clearance or GFR > 60 mL/min/1.73m^2. If a creatinine clearance is performed at end induction and the result is < 100 ml/min/1.73m^2, a GFR must then be performed using a nuclear blood sampling method or iothalamate clearance method. Camera method is NOT allowed as measure of GFR prior to or during Consolidation therapy for patients with GFR or creatinine clearance of < 100 ml/min/1.73m^2 - Recovery from acute toxicities of last cycle of induction chemotherapy - Appropriate written consent - adult or parent/guardian if patient is < 18 years of age and minor information sheet if patient is > 8 years of age


NCT ID:

NCT02605421


Primary Contact:

Principal Investigator
Heather Stefanski, MD
Masonic Cancer Center, University of Minnesota

Kim Nelson
Phone: 612-273-2925
Email: knelso62@fairview.org


Backup Contact:

Email: stef0030@umn.edu
Heather Stefanski, MD
Phone: (612) 624-0123


Location Contact:

Minneapolis, Minnesota 55455
United States

Kim Nelson, RN
Phone: 612-273-2925
Email: knelso62@fairview.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.